MedTrace Logo

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

NCT00846612 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-09-30

No results posted yet for this study

Summary

This study is to study pharmacokinetics of Doxil using Doxil and Avastin on ovarian cancer patients who are resistant to or have relapsed from platinum-based therapy.

Conditions

Interventions

DRUG

Doxil

1 cycle: 3 weeks; 30 mg/m\^2, IV, every cycle

DRUG

Bevacizumab (Avastin)

1 cycle: every 3 weeks; 15 mg/kg, IV, beginning on cycle 2 and every cycle 20-24 hours following Doxil administration

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • University of New Mexico Cancer Center

    collaborator OTHER

  • NYU Langone Health

    lead OTHER

Principal Investigators

  • Franco Muggia, MD · NYU Langone Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-09-30
Completion
2012-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00846612 on ClinicalTrials.gov